GLUE
Monte Rosa Therapeutics Inc
NASDAQ: GLUE · HEALTHCARE · BIOTECHNOLOGY
$20.39
+5.37% today
Updated 2026-05-06
Market cap
$1.50B
P/E ratio
—
P/S ratio
12.16x
EPS (TTM)
$-0.46
Dividend yield
—
52W range
$4 – $26
Volume
1.1M
Monte Rosa Therapeutics Inc (GLUE) Financial statements
SEC filings — annual and quarterly data.
Cash flow — annual
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | $-6.17M | $-23.05M | $-59.36M | $-92.47M | $-43.80M | $42.00M | $-22.80M |
| Capital expenditures | $1.39M | $3.39M | $9.73M | $12.91M | $19.04M | $3.99M | $4.70M |
| Depreciation | $72000.00 | $537000.00 | $2.13M | $3.75M | $6.22M | $8.12M | — |
| Stock-based comp | $0.00 | $354000.00 | $5.20M | $11.66M | $16.67M | $18.13M | $18.86M |
| Free cash flow | $-7.56M | $-26.44M | $-69.09M | $-105.38M | $-62.84M | $38.01M | $-27.50M |
| Investing cash flow | $-1.39M | $-3.39M | $-9.65M | $-219.22M | $88.80M | $-44.45M | — |
| Financing cash flow | $15.00M | $60.06M | $377.56M | $20.47M | $27.49M | $98.89M | — |
| Dividends paid | — | — | — | — | — | — | — |
| Share repurchases | — | — | — | — | — | — | — |
| Debt repayment | — | — | — | — | — | — | — |
| Net change in cash | — | — | $308.55M | $-291.22M | — | — | — |